CN111388571A - 一种治疗鼻炎和感冒的复方精油 - Google Patents
一种治疗鼻炎和感冒的复方精油 Download PDFInfo
- Publication number
- CN111388571A CN111388571A CN202010152776.0A CN202010152776A CN111388571A CN 111388571 A CN111388571 A CN 111388571A CN 202010152776 A CN202010152776 A CN 202010152776A CN 111388571 A CN111388571 A CN 111388571A
- Authority
- CN
- China
- Prior art keywords
- essential oil
- oil
- parts
- cold
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 168
- 150000001875 compounds Chemical class 0.000 title claims abstract description 58
- 206010039083 rhinitis Diseases 0.000 title claims abstract description 39
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000005979 Citrus limon Nutrition 0.000 claims abstract description 16
- 244000131522 Citrus pyriformis Species 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 239000002199 base oil Substances 0.000 claims abstract description 15
- 244000223014 Syzygium aromaticum Species 0.000 claims abstract description 13
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims abstract description 13
- 235000007303 Thymus vulgaris Nutrition 0.000 claims abstract description 13
- 239000001585 thymus vulgaris Substances 0.000 claims abstract description 13
- 244000166124 Eucalyptus globulus Species 0.000 claims abstract description 12
- 240000005125 Myrtus communis Species 0.000 claims abstract description 12
- 235000013418 Myrtus communis Nutrition 0.000 claims abstract description 12
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 claims abstract description 10
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 claims abstract description 10
- 229930007744 linalool Natural products 0.000 claims abstract description 10
- 235000004692 Eucalyptus globulus Nutrition 0.000 claims abstract description 8
- 241000378467 Melaleuca Species 0.000 claims abstract description 4
- 244000075634 Cyperus rotundus Species 0.000 claims abstract description 3
- 235000016854 Cyperus rotundus Nutrition 0.000 claims abstract description 3
- 244000178860 Lavandula latifolia Species 0.000 claims abstract description 3
- 235000010658 Lavandula latifolia Nutrition 0.000 claims abstract description 3
- 240000002657 Thymus vulgaris Species 0.000 claims abstract 4
- 244000144725 Amygdalus communis Species 0.000 claims description 11
- 235000011437 Amygdalus communis Nutrition 0.000 claims description 11
- 239000008168 almond oil Substances 0.000 claims description 11
- 235000021302 avocado oil Nutrition 0.000 claims description 11
- 239000008163 avocado oil Substances 0.000 claims description 11
- 239000008169 grapeseed oil Substances 0.000 claims description 11
- 229940119170 jojoba wax Drugs 0.000 claims description 11
- 239000010497 wheat germ oil Substances 0.000 claims description 11
- 244000178870 Lavandula angustifolia Species 0.000 claims description 9
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims description 9
- 239000001102 lavandula vera Substances 0.000 claims description 9
- 235000018219 lavender Nutrition 0.000 claims description 9
- 244000304222 Melaleuca cajuputi Species 0.000 claims description 7
- 235000001167 Melaleuca cajuputi Nutrition 0.000 claims description 7
- 235000017710 Melaleuca viridiflora Nutrition 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 5
- 240000005592 Veronica officinalis Species 0.000 claims description 4
- 235000010465 Veronica officinalis Nutrition 0.000 claims description 4
- -1 jojoba oil Substances 0.000 claims description 3
- 238000004097 X-ray Buerger Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 49
- 239000003814 drug Substances 0.000 abstract description 19
- 206010039101 Rhinorrhoea Diseases 0.000 abstract description 14
- 229940079593 drug Drugs 0.000 abstract description 13
- 208000002173 dizziness Diseases 0.000 abstract description 12
- 206010019233 Headaches Diseases 0.000 abstract description 9
- 231100000869 headache Toxicity 0.000 abstract description 9
- 201000009240 nasopharyngitis Diseases 0.000 abstract description 7
- 206010011224 Cough Diseases 0.000 abstract description 6
- 206010057190 Respiratory tract infections Diseases 0.000 abstract description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 5
- 206010028748 Nasal obstruction Diseases 0.000 abstract description 5
- 125000003118 aryl group Chemical group 0.000 abstract description 5
- 208000026435 phlegm Diseases 0.000 abstract description 5
- 210000004072 lung Anatomy 0.000 abstract description 4
- 241000196324 Embryophyta Species 0.000 abstract description 3
- 208000036071 Rhinorrhea Diseases 0.000 abstract description 3
- 206010046306 Upper respiratory tract infection Diseases 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 238000007599 discharging Methods 0.000 abstract description 2
- 230000035945 sensitivity Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 210000001331 nose Anatomy 0.000 description 28
- 208000024891 symptom Diseases 0.000 description 25
- 230000029058 respiratory gaseous exchange Effects 0.000 description 14
- 238000000034 method Methods 0.000 description 11
- 210000003928 nasal cavity Anatomy 0.000 description 11
- 208000010753 nasal discharge Diseases 0.000 description 11
- 241000246358 Thymus Species 0.000 description 9
- 206010037660 Pyrexia Diseases 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 238000003825 pressing Methods 0.000 description 7
- 206010039085 Rhinitis allergic Diseases 0.000 description 6
- 201000010105 allergic rhinitis Diseases 0.000 description 6
- 238000004898 kneading Methods 0.000 description 6
- 229930003658 monoterpene Natural products 0.000 description 6
- 235000002577 monoterpenes Nutrition 0.000 description 6
- 206010063659 Aversion Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 150000002773 monoterpene derivatives Chemical class 0.000 description 5
- 210000003097 mucus Anatomy 0.000 description 5
- 210000002345 respiratory system Anatomy 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 206010006451 bronchitis Diseases 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 206010062519 Poor quality sleep Diseases 0.000 description 3
- 206010039792 Seborrhoea Diseases 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- SZGZILRQIYNODJ-UHFFFAOYSA-L disodium;7,12-dihydroquinoxalino[3,2-b]phenazine-2,9-disulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC=C2N=C(C=C3C(NC4=CC=C(C=C4N3)S(=O)(=O)[O-])=C3)C3=NC2=C1 SZGZILRQIYNODJ-UHFFFAOYSA-L 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- 235000008671 Calycanthus floridus Nutrition 0.000 description 2
- 235000008670 Calycanthus occidentalis Nutrition 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 2
- PSMFFFUWSMZAPB-UHFFFAOYSA-N Eukalyptol Natural products C1CC2CCC1(C)COCC2(C)C PSMFFFUWSMZAPB-UHFFFAOYSA-N 0.000 description 2
- 244000148992 Lindera benzoin Species 0.000 description 2
- 235000004520 Lindera benzoin Nutrition 0.000 description 2
- 235000008262 Lindera benzoin var. benzoin Nutrition 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 206010072170 Skin wound Diseases 0.000 description 2
- 241001278775 Veronicastrum Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- UWKAYLJWKGQEPM-LBPRGKRZSA-N linalyl acetate Chemical compound CC(C)=CCC[C@](C)(C=C)OC(C)=O UWKAYLJWKGQEPM-LBPRGKRZSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000037312 oily skin Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 206010041232 sneezing Diseases 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- LKMWMGHBXUBJSR-UHFFFAOYSA-N (4-hydroxy-3,5-dimethoxyphenyl)methyl acetate Chemical compound COC1=CC(COC(C)=O)=CC(OC)=C1O LKMWMGHBXUBJSR-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 241001290610 Abildgaardia Species 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- NOQGZXFMHARMLW-UHFFFAOYSA-N Daminozide Chemical group CN(C)NC(=O)CCC(O)=O NOQGZXFMHARMLW-UHFFFAOYSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000008017 Hypohidrosis Diseases 0.000 description 1
- 208000032034 Increased viscosity of nasal secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000334160 Isatis Species 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000366182 Melaleuca alternifolia Species 0.000 description 1
- 208000001705 Mouth breathing Diseases 0.000 description 1
- 241000219926 Myrtaceae Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- 244000045719 Syzygium Species 0.000 description 1
- 235000012096 Syzygium samarangense Nutrition 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 206010002512 anhidrosis Diseases 0.000 description 1
- 230000037001 anhydrosis Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 238000000222 aromatherapy Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- UWKAYLJWKGQEPM-UHFFFAOYSA-N linalool acetate Natural products CC(C)=CCCC(C)(C=C)OC(C)=O UWKAYLJWKGQEPM-UHFFFAOYSA-N 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 210000001944 turbinate Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000009792 yinqiao Substances 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
- A61K36/835—Aquilaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗鼻炎和感冒的复方精油,涉及医药技术领域,所述复方精油由如下质量份数的原料组成:沉香醇百里香精油0.5%‑1%、丁香花苞精油0.5%‑1%、穗花薰衣草精油1%‑2%、香桃木精油1%‑2%、蓝胶尤加利精油1%‑2%、罗文莎叶精油2%‑3%、绿花白千层精油2%‑3%、柠檬精油0.5%‑1%、余量为基础油。本发明的复方精油对于鼻炎的鼻塞、流涕、鼻部敏感等及感冒头疼头昏有显著效果,对于上呼吸道感染引起咳嗽、痰液无法排出,有止咳、宣肺、排痰的效果,本发明的复方精油使用纯植物提取的芳香物质,抗病毒、抗菌、提升自身免疫力,安全环保,无毒副作用。
Description
技术领域
本发明涉及医药技术领域,具体涉及一种治疗鼻炎和感冒的复方精油。
背景技术
感冒和鼻炎是常见的上呼吸道感染疾病,给患者带来很大痛苦,目前市场上治疗鼻炎和感冒的药物众多,临床常用的治疗鼻炎的药物有丙酸倍氯米松、布地奈德、丙酸氟替卡松和糠酸莫米松等,其均属第二代鼻用糖皮质激素,虽然这些治疗鼻炎的药物临床疗效已得到充分验证,但是这些药物如果长期使用,都容易产生耐药性,或破坏鼻腔内环境,纤毛破损,引起药物性鼻炎,加重病情。治疗感冒的药物有银翘解毒片、感冒退热冲剂、板蓝根、阿司匹林、扑尔敏、氯雷他定、奥司他韦、扎那米韦等,这些药物中的西药副作用大,患者服用后多感头晕、瞌睡等,有的还会刺激胃肠道,甚至损害肝脏、肾脏,对老人、小孩尤其不宜,这些药物中的中药存在起效慢,用药量大,对症状不能直接干预,疗效普通不佳,并也有一定的副作用。
发明内容
为此,本发明提供一种治疗鼻炎和感冒的复方精油,以解决现有治疗鼻炎和感冒的药物存在容易产生耐药性、副作用大、疗效不佳等问题。
为了实现上述目的,本发明提供如下技术方案:
根据本发明的第一方面,一种治疗鼻炎和感冒的复方精油,所述复方精油由如下质量份数的原料组成:沉香醇百里香精油0.5%-1%、丁香花苞精油0.5%-1%、穗花薰衣草精油1%-2%、香桃木精油1%-2%、蓝胶尤加利精油1%-2%、罗文莎叶精油2%-3%、绿花白千层精油2%-3%、柠檬精油0.5%-1%、余量为基础油。
进一步地,所述复方精油由如下质量份数的原料组成:沉香醇百里香精油0.5%、丁香花苞精油0.5%、穗花薰衣草精油1%、香桃木精油1%、蓝胶尤加利精油1%、罗文莎叶精油2%、绿花白千层精油2%、柠檬精油0.5%、基础油91.5%。
进一步地,所述复方精油由如下质量份数的原料组成:沉香醇百里香精油1%、丁香花苞精油1%、穗花薰衣草精油2%、香桃木精油2%、蓝胶尤加利精油2%、罗文莎叶精油3%、绿花白千层精油3%、柠檬精油1%、基础油85%。
进一步地,所述基础油为小麦胚芽油、荷荷巴油、酪梨油、甜杏仁油和葡萄籽油的混合物。
进一步地,所述基础油中原料的重量份数如下:小麦胚芽油0.5-1.5份、荷荷巴油2-3份、酪梨油3-5份、甜杏仁油18-20份、葡萄籽油60-65份。
进一步地,所述基础油中原料的重量份数如下:小麦胚芽油1份、荷荷巴油3份、酪梨油5份、甜杏仁油20份,葡萄籽油62.5份。
进一步地,所述基础油中原料的重量份数如下:小麦胚芽油1份、荷荷巴油2份、酪梨油3份、甜杏仁油18份,葡萄籽油61份。
沉香醇百里香精油,沉香醇百里香中含有大量的温和型沉香醇,亲肤性极高,且容易取得,其气味清新甜美,适用范围广泛。沉香醇百里香精油能应用于处理因感冒引发的耳鼻喉问题,或支气管炎、肠胃炎、膀胱炎等感染问题,同时能鼓舞因生病而低落的情绪。
丁香花苞精油,是由桃金娘科蒲桃属乔木丁香提炼而来的挥发性芳香物质,在欧洲,有“家庭牙医”之称。其中的丁香酚和乙酸丁香酯有强力抗感染、抗菌,消炎的作用。可治疗牙痛、支气管炎,神经痛、胃酸,减轻痢疾所造成之不适与疼痛,改善衰弱体质与贫血,驱虫。促进血液循环,治疗皮肤溃疡及伤口发炎,治疗疥癣,改善粗糙肌肤。
穗花薰衣草精油,是由薰衣草提炼而成提炼出来的精油,它被人熟悉的功效如:止痛、抗忧郁、消毒、杀菌和解除充血与肿胀的功用,以及降血压、驱虫、镇定和回复健康的效果。其中,1,8-桉油醇和单萜酮,使它对呼吸道问题也有非常好的抗菌效果;同时,沉香醇温和的特质,尤其可以处理幼童的咳嗽问题。
香桃木精油,除了富含1,8-桉油醇,其中乙酸沉香酯可以在不干扰睡眠的状态下,处理呼吸道的问题。它的整体功效具有抗菌、收敛、杀菌、祛肠胃胀气、化痰、杀寄生虫的功效,能净化肌肤,收缩毛孔,也可治疗痤疮及留下来的疤痕;具有净化功能,对气喘、慢性支气管炎、鼻窦炎以及感冒引起的呼吸道感染都很有效;酯类物质能够镇静激动的情绪,使人心平气和。
蓝胶尤加利精油,尤加利是常用的呼吸道类精油,其富含有1,8桉油醇以及少量单萜烯酮类的松香芹酮,具有高度化痰功效,可用于治疗呼吸道感染的感冒症状。
罗文莎叶精油,罗文莎叶属于樟科植物,所以整科植物都很芬芳,而从树皮、树叶到果实都被人们作为香料增味和医疗用途,能缓解呼吸不适,对于感冒、呼吸道感染有极佳的改善力。它氧化物和单萜烯的成分,使它在应用过程中起效快,同时单萜醇又是温和而安全的,罗文莎叶精油对皮肤非常安全,又具有强效的抗病毒杀菌作用,连儿童使用都很适合。
绿花白千层精油,在发明抗生素前,法国用来杀菌消毒、抗菌,替代抗生素使用。其包括如下疗效:1、基本疗效:可以清洁轻微的创伤和烧伤,不刺激皮肤;又是良好的杀菌剂,因此也非常适合治疗痤疮等皮肤病。2、皮肤疗效:用于皮肤的溃疡、创伤,能促进伤口愈合;平衡油脂分泌,改善油性肌肤及油性头皮的油脂分泌量,能改善青春痘及减缓头皮屑的状况。3、心理疗效:具有激励的作用,可使头脑清醒,集中注意力。4、生理疗效:以抗菌力著称,对胸腔方面的传染病非常有帮助,像慢性支气管炎、肺结核、肺炎或是流行性感冒引起的喉炎、咳嗽都有效,甚至气喘、鼻炎、鼻窦炎都可以用。它同时有大量的单萜醇和倍半萜醇,又使它的成分很安全,它的强项在于温和而缓慢地处理问题,我们知道祛病如抽丝,在搭配了快速起效的成分的同时,它是抽丝剥茧的清理问题根源的存在。也因为它的安全性,儿童可用。
柠檬精油,柠檬是我们熟悉的水果之一,柠檬清新的香气,可以提神醒脑、振奋精神,缓解烦躁,净化空气。柠檬精油对于皮肤及身体也有很多积极的调理作用。熟知的柠檬精油中的柠檬烯特别有益于美白、收敛、平衡油脂分泌、治疗青春痘等油性皮肤症状。此外,它的单萜烯成分,使它成为抗炎的佼佼者。
本发明具有如下优点:
本发明一种治疗鼻炎和感冒的复方精油中沉香醇百里香精油、丁香花苞精油、穗花薰衣草精油、香桃木精油、蓝胶尤加利精油、罗文莎叶精油、绿花白千层精油、柠檬精油因为各自成分的不同,单独使用时只能体现各自的功效,通过这八种功能精油的合理配伍及相互协同作用,能够改变病毒的生长环境,抑制病毒侵入体内,持续不断的改善鼻腔环境,帮助新生的粘膜更健康,通过复方配方中醒脑通窍的精油成分,改善头疼头昏的不适感。该复方精油能够化痰宣肺,帮助痰液排出,缓解上呼吸道的整体不适,还能够带动身体的自身循环系统,运化行气,提升整体免疫力水平。
本发明一种治疗鼻炎和感冒的复方精油使用纯植物提取的芳香物质,抗病毒、抗菌、提升自身免疫力,安全环保,无毒副作用。
具体实施方式
以下由特定的具体实施例说明本发明的实施方式,熟悉此技术的人士可由本说明书所揭露的内容轻易地了解本发明的其他优点及功效,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
一种治疗鼻炎和感冒的复方精油,所述复方精油由如下质量份数的原料组成:沉香醇百里香精油0.5%、丁香花苞精油0.5%、穗花薰衣草精油1%、香桃木精油1%、蓝胶尤加利精油1%、罗文莎叶精油2%、绿花白千层精油2%、柠檬精油0.5%、小麦胚芽油1%、荷荷巴油3%、酪梨油5%、甜杏仁油20%,葡萄籽油62.5%。
该复方精油的制备方法如下:按上述重量份数称取各原料油,充分搅拌均匀即可。
实施例2
一种治疗鼻炎和感冒的复方精油,所述复方精油由如下质量份数的原料组成:沉香醇百里香精油1%、丁香花苞精油1%、穗花薰衣草精油2%、香桃木精油2%、蓝胶尤加利精油2%、罗文莎叶精油3%、绿花白千层精油3%、柠檬精油1%、小麦胚芽油1%、荷荷巴油2%、酪梨油3%、甜杏仁油18%,葡萄籽油61%。
该复方精油的制备方法同实施例1。
实施例3
一种治疗鼻炎和感冒的复方精油,所述复方精油由如下质量份数的原料组成:沉香醇百里香精油0.8%、丁香花苞精油0.8%、穗花薰衣草精油1.5%、香桃木精油1.5%、蓝胶尤加利精油1.5%、罗文莎叶精油2.5%、绿花白千层精油2.5%、柠檬精油0.8%、小麦胚芽油1.5%、荷荷巴油2.5%、酪梨油4%、甜杏仁油19%,葡萄籽油61.1%。
该复方精油的制备方法同实施例1。
本发明一种治疗鼻炎和感冒的复方精油对于鼻炎的鼻塞、流涕、鼻部敏感等及感冒头疼头昏有显著效果,对于上呼吸道感染引起咳嗽、痰液无法排出,有止咳、宣肺、排痰的效果。以下分别针对鼻炎患者和感冒患者的临床试验来说明本发明复方精油的功效。
1、一般资料
本发明的复方精油对100例患有鼻炎和感冒的病人进行疗效观察,其中,鼻炎患者60人,感冒患者40人,患者均为成年人。
2、治疗方法:
本发明的复方精油的使用方法如下:用棉签取本品适量涂抹鼻腔内,有利于抗病毒、抗感染,直接呵护发炎的呼吸道;搓热整个鼻体,上下搓揉,再取本品1滴涂于鼻翼两侧或鼻子周围,稍用力点按迎香穴和/或睛明穴和/或印堂穴30秒至1分钟左右,有利于缓解鼻塞、通畅鼻窍。
本发明的复方精油不可香薰、不可内服。
3、诊断标准
鼻炎的诊断标准:西医诊断标准遵循1997年中华医学会中华耳鼻喉科学分会、《中华耳鼻咽喉科杂志》编辑委员会“变应性鼻炎诊断标准及疗效评定标准”,中医诊断标准遵循国家中医药管理局颁布的《中医病症诊断疗效标准》。
感冒的诊断标准:从五个系列症状出发来做判断:
①卫表系列。恶寒发热或暂不发热,头痛,身困,有汗或无汗,脉浮,舌苔薄白。
②肺卫系列。恶寒发热,有汗或无汗,咳嗽,喷嚏,鼻塞,流涕,咽痛,脉浮数,舌苔薄黄。
③太阳经系列。恶寒发热,头痛,项背不适,身痛,无汗,腰背酸痛,脉浮紧,舌苔薄白。
④胃肠系列。恶寒发热,恶心,口苦,呕吐,腹痛,腹泻,脉浮滑,舌苔偏腻,色白或黄。
⑤混合系列。恶寒发热,头痛,身痛,咳嗽,咽痛,呕吐,腹痛,腹泻,脉浮滑数,舌苔白干。
凡具备①、②、③、④系列中任何一个系列症状者,即可诊断为感冒。
4、疗效评定标准
鼻炎疗效评定标准:根据症状分级记分标准量表评分统计有效率(尼莫地平法):有效率=(治疗前积分-治疗后积分)/治疗前积分×100%,①显效:疗效指数≥51%;②有效:21%≤疗效指数≤50%;③无效:疗效指数≤20%。总有效率=显效率+有效率。
感冒疗效评定标准:①显效:使用24小时内,全身及局部主要症状如发热、流涕等消失或基本消退;②有效:使用24-48小时内,全身及局部主要症状如发热、流涕等消失或基本消退;③无效:不符合以上标准者均为无效。总有效率=显效率+有效率。
5、治疗结果
根据临床统计,本发明的复方精油治疗鼻炎的显效为45例,有效为15例,无效为0例;治疗感冒的显效为20例,有效为20例,无效为0例;由此可以看出本发明的复方精油对鼻炎和感冒的有效率均达100%,能有效地治疗鼻炎和感冒。医生可以根据病人症状的轻重,根据配方适当调整复方精油中功能精油的总量占比,轻度和中度症状患者可以选择使用实施例1或3的复方精油,重度或者急性患者可以选择使用实施例2的复方精油。
典型案例
案例一:杨先生,31岁,患过敏性鼻炎近20年。来就诊之前症状包括:1、早起易流浊涕,遇风寒加重;2、灰尘、柳絮易引起过敏,鼻腔红肿,无法闻到味道,呼吸不畅;3、平时主要口呼吸;睡时张嘴呼吸;4、因为呼吸不畅,睡眠差,情绪差。来就诊后,建议使用实施例2的复方精油,具体使用方法:1、两滴于鼻子表面,点按迎香穴1分钟;2、搓热整个鼻体,上下搓揉;3、涂抹1滴精油于鼻腔内部。使用本发明的复方精油后的效果:1、点按迎香穴后鼻子呼吸通畅感明显;2、鼻腔红肿每天按揉都有减轻,一周后症状消失;3、使用三天后鼻涕开始减少,一周后不流鼻涕;4、使用后呼吸通畅,三天后睡眠有明显的改善,一周后睡眠恢复正常。
案例二:韩先生,28岁,患过敏性鼻炎近10年。来就诊之前症状包括:1、冷热交替时易引起鼻炎发作,流涕增多,多为清涕;2、打喷嚏;3、鼻腔红肿呼吸不畅,头晕头疼。来就诊后,建议使用实施例2的复方精油,具体使用方法:1、两滴于鼻子表面,点按迎香穴2分钟,早晚各一次;2、搓热整个鼻体,上下搓揉,点按睛明穴与印堂穴;3、涂抹1滴精油于鼻腔内部。使用本发明的复方精油后的效果:1、点按迎香穴后鼻子呼吸通畅感明显;2、每天按揉印堂穴与睛明穴,2天后头痛头晕症状消失;3、红肿症状按摩鼻子3~4天症状慢慢消失;4、使用2天后鼻涕开始减少,4天后不流鼻涕。
案例三:张先生,56岁,患过敏性鼻炎近30年。来就诊之前症状包括:1、鼻子呼吸不畅,主要靠口呼吸;2、睡眠差,打呼噜严重;3、头晕。来就诊后,建议使用实施例2的复方精油,每天一次,具体使用方法:1、涂抹芳香清润精油两滴于鼻子表面,点按迎香穴1分钟;2、搓热整个鼻体,上下搓揉;3、涂抹1滴精油于鼻腔内部。使用本发明的复方精油后的效果:1、前3天点按迎香穴未见明显呼吸通畅感,但鼻涕增多,从第4天开始能够闻见味道且呼吸有明显的通畅感;2、第一天按揉后头晕的感觉有明显的改善,第4天呼吸较为通畅后,头晕症状消失。3、睡眠因呼吸通畅睡得比较深,不会因呼吸不畅而憋醒,口呼吸症状缓解。
案例四:辛先生,58岁,患过敏性鼻炎30多年。来就诊之前症状包括:鼻腔堵塞影响呼吸,睡眠受呼吸影响差。来就诊后,建议使用实施例2的复方精油,每天一次,具体使用方法:1、取一滴复方精油滴于鼻子表面,按揉迎香穴1分钟;2、搓热整个鼻体,上下搓揉。使用本发明的复方精油后的效果:1、揉搓鼻腔外部和点按迎香穴后会明显感觉呼吸的通畅感和清凉感;2、涂抹后,开始鼻涕会多,过后会得到缓解,不会像鼻炎持续性流涕,鼻炎引起的呼吸问题在一周左右得到缓解。
案例五:韩先生,38岁,鼻甲肥大,患过敏性鼻炎20多年。来就诊之前症状包括:1、鼻子不通气,需要喷剂进行物理刺激;2、经常擤鼻涕;3、呼吸不通常导致睡眠质量差。来就诊后,建议使用实施例2的复方精油,每天一次,具体使用方法:1、涂抹芳香清润精油两滴于鼻子表面,点按迎香穴1分钟;2、搓热整个鼻体,上下搓揉;3、涂抹1滴精油于鼻腔内部。使用本发明的复方精油后的效果:1、点按之后,会先帮助把鼻子里面积攒的液体排出,之前是干擤鼻涕;随之,通畅感增加,呼吸顺畅;2、5天后呼吸较以往明显通畅;3、10天后,基本脱离喷剂的物理刺激。
案例六:赵女士,58岁,感冒。来就诊之前症状包括:流鼻涕,打喷嚏,眩晕,没精神。来就诊后,建议使用实施例1的复方精油,每天一次,具体使用方法:1、取精油两滴于鼻子表面进行涂抹,点按迎香穴1分钟;2、搓热整个鼻体,上下搓揉;3、涂抹1滴精油于鼻腔内部。使用本发明的复方精油后的效果:1、点按迎香穴后当时鼻子呼吸通畅感明显,感冒症状缓解,连续用2天鼻涕由多减少;2、第1天按揉后头晕的感觉有明显改善,第2天呼吸通畅后,头晕症状消失。
案例七:贾女士,50岁,感冒初期。来就诊之前症状包括:鼻塞不畅通,头疼头晕,症状较轻。来就诊后,建议使用实施例1的复方精油,每天一次,具体使用方法:将本发明复方精油涂抹于鼻子下面,人中及横向位置使用。使用本发明的复方精油后的效果:使用本发明复方精油30秒后感觉鼻子通畅了,一两分钟后,头痛感消失。
虽然,上文中已经用一般性说明及具体实施例对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (7)
1.一种治疗鼻炎和感冒的复方精油,其特征在于,所述复方精油由如下质量份数的原料组成:沉香醇百里香精油0.5%-1%、丁香花苞精油0.5%-1%、穗花薰衣草精油1%-2%、香桃木精油1%-2%、蓝胶尤加利精油1%-2%、罗文莎叶精油2%-3%、绿花白千层精油2%-3%、柠檬精油0.5%-1%、余量为基础油。
2.如权利要求1所述的一种治疗鼻炎和感冒的复方精油,其特征在于,所述复方精油由如下质量份数的原料组成:沉香醇百里香精油0.5%、丁香花苞精油0.5%、穗花薰衣草精油1%、香桃木精油1%、蓝胶尤加利精油1%、罗文莎叶精油2%、绿花白千层精油2%、柠檬精油0.5%、基础油91.5%。
3.如权利要求1所述的一种治疗鼻炎和感冒的复方精油,其特征在于,所述复方精油由如下质量份数的原料组成:沉香醇百里香精油1%、丁香花苞精油1%、穗花薰衣草精油2%、香桃木精油2%、蓝胶尤加利精油2%、罗文莎叶精油3%、绿花白千层精油3%、柠檬精油1%、基础油85%。
4.如权利要求1所述的一种治疗鼻炎和感冒的复方精油,其特征在于,所述基础油为小麦胚芽油、荷荷巴油、酪梨油、甜杏仁油和葡萄籽油的混合物。
5.如权利要求4所述的一种治疗鼻炎和感冒的复方精油,其特征在于,所述基础油中原料的重量份数如下:小麦胚芽油0.5-1.5份、荷荷巴油2-3份、酪梨油3-5份、甜杏仁油18-20份、葡萄籽油60-65份。
6.如权利要求5所述的一种治疗鼻炎和感冒的复方精油,其特征在于,所述基础油中原料的重量份数如下:小麦胚芽油1份、荷荷巴油3份、酪梨油5份、甜杏仁油20份,葡萄籽油62.5份。
7.如权利要求5所述的一种治疗鼻炎和感冒的复方精油,其特征在于,所述基础油中原料的重量份数如下:小麦胚芽油1份、荷荷巴油2份、酪梨油3份、甜杏仁油18份,葡萄籽油61份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010152776.0A CN111388571A (zh) | 2020-03-06 | 2020-03-06 | 一种治疗鼻炎和感冒的复方精油 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010152776.0A CN111388571A (zh) | 2020-03-06 | 2020-03-06 | 一种治疗鼻炎和感冒的复方精油 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111388571A true CN111388571A (zh) | 2020-07-10 |
Family
ID=71410868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010152776.0A Pending CN111388571A (zh) | 2020-03-06 | 2020-03-06 | 一种治疗鼻炎和感冒的复方精油 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111388571A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112826848A (zh) * | 2021-03-02 | 2021-05-25 | 张容真 | 一种缓解过敏性鼻炎及感冒症状的复方植物精油及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101947267A (zh) * | 2010-10-11 | 2011-01-19 | 上海应用技术学院 | 一种固体芳香抗晕剂及其制备方法 |
CN102319292A (zh) * | 2011-08-04 | 2012-01-18 | 张玲环 | 治疗鼻炎的精油组分及其应用 |
CN103054989B (zh) * | 2013-01-23 | 2014-07-16 | 云南伊纳姿生物科技有限公司 | 一种用于预防和治疗牛皮癣的复方精油及其制备方法 |
CN107088170A (zh) * | 2017-04-28 | 2017-08-25 | 广州栋方生物科技股份有限公司 | 一种舒缓复方精油及其制备方法和应用 |
-
2020
- 2020-03-06 CN CN202010152776.0A patent/CN111388571A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101947267A (zh) * | 2010-10-11 | 2011-01-19 | 上海应用技术学院 | 一种固体芳香抗晕剂及其制备方法 |
CN102319292A (zh) * | 2011-08-04 | 2012-01-18 | 张玲环 | 治疗鼻炎的精油组分及其应用 |
CN103054989B (zh) * | 2013-01-23 | 2014-07-16 | 云南伊纳姿生物科技有限公司 | 一种用于预防和治疗牛皮癣的复方精油及其制备方法 |
CN107088170A (zh) * | 2017-04-28 | 2017-08-25 | 广州栋方生物科技股份有限公司 | 一种舒缓复方精油及其制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
国产非特殊用途化妆品备案信息服务平台: "《http://ftba.nmpa.gov.cn:8181/ftban/itownet/hzp_ba/fw/pz.jsp?processid=201909111744208wype&nid=201909111744208wype》" * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112826848A (zh) * | 2021-03-02 | 2021-05-25 | 张容真 | 一种缓解过敏性鼻炎及感冒症状的复方植物精油及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105615586A (zh) | 一种具有净化空气功能的苦楝皮地毯 | |
CN109224019A (zh) | 一种用于治疗鼻炎的中药组合物、其制备方法及中药制剂 | |
CN111388571A (zh) | 一种治疗鼻炎和感冒的复方精油 | |
CN108452178A (zh) | 一种治疗鼻炎的药物及其制备方法 | |
CN103877288B (zh) | 一种壳聚糖鼻咽生物医用膜及其制备方法 | |
CN104258455A (zh) | 一种医用生物抗菌敷料及其制备方法 | |
Hoffmann | Easy breathing: natural treatments for asthma, colds, flu, coughs, allergies, and sinusitis | |
CN106309746A (zh) | 一种中药组合物及其制备方法和口腔保健品 | |
CN105250385A (zh) | 一种治疗婴幼儿鼻塞的滴鼻剂 | |
CN108420102A (zh) | 一种治疗鼻炎的卷烟配方及工艺 | |
CN104206444B (zh) | 一种含有薰衣草天然芳香的电热液体蚊香及制备方法 | |
CN109106774B (zh) | 一种治疗腺样体肥大及其并发症的中药组合物及其制备方法和应用 | |
WO2021251617A1 (ko) | 비염 완화 또는 치료용 생약 조성물, 이를 포함하는 한방 약침액, 이를 포함하는 주사제 및 이를 이용한 약침 침술방법 | |
CN103083404A (zh) | 鼻腔保护剂 | |
CN106619934A (zh) | 一种快速调节呼吸道和预防感冒的外用能量油 | |
CN103316136A (zh) | 治疗鼻炎的外用中药药油 | |
CN111035684A (zh) | 一种臭氧油复方鼻炎凝胶及其制备方法 | |
CN111494520A (zh) | 一种治疗鼻炎的药物及其制备方法和应用 | |
CN110893217A (zh) | 一种具有戒烟保健功能的中药香液及制备方法 | |
CN114099579B (zh) | 一种治疗腺样体肥大及其并发症的中药组合物及其制备方法和应用 | |
CN107982321A (zh) | 一种鼻塞用通气油及其制备方法和应用 | |
CN116585404B (zh) | 一种治疗成人单纯性皮肤瘙痒症的外用中药组合物及制备方法 | |
Kanj | Natural Expectorants to Relieve a Cough | |
CN111358927B (zh) | 蒲姜药物组合物及其应用 | |
Dhar et al. | Medicinal Plants of India |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200710 |
|
RJ01 | Rejection of invention patent application after publication |